- Home
- PB vs IBRX Comparison
PB vs IBRX Comparison
Compare PB & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PB | IBRX |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.1B |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | PB | IBRX |
|---|---|---|
| Price | $66.63 | $5.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $81.17 | $11.80 |
| AVG Volume (30 Days) | 784.0K | ★ 49.3M |
| Earning Date | 01-28-2026 | 03-02-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | ★ 19.26 | N/A |
| EPS | ★ 5.60 | N/A |
| Revenue | ★ $1,239,671,000.00 | $82,555,000.00 |
| Revenue This Year | $8.85 | $680.06 |
| Revenue Next Year | $20.42 | $90.18 |
| P/E Ratio | $13.02 | ★ N/A |
| Revenue Growth | 7.88 | ★ 1025.95 |
| 52 Week Low | $61.07 | $1.83 |
| 52 Week High | $82.75 | $8.28 |
Technical Indicators
Market Signals| Indicator | PB | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.24 | 66.01 |
| Support Level | $71.34 | $5.71 |
| Resistance Level | $73.26 | $8.28 |
| Average True Range (ATR) | 1.77 | 0.73 |
| MACD | -0.42 | 0.21 |
| Stochastic Oscillator | 13.87 | 56.43 |
Price Performance
Historical ComparisonAbout PB Prosperity Bancshares Inc.
Prosperity Bancshares Inc provides retail and commercial banking services to individuals and small to midsize businesses. It provides a wide array of financial products and services to businesses and consumers throughout Texas and Oklahoma. The group provides Personal, Business, Mortgage, and Banking Services.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.